A post-marketing surveillance (PMS) study to monitor the safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ human papillo-mavirus (HPV) vaccine (Cervarix) in 3,000 healthy female Filipino subjects when administered according to the Prescribing Information from the age of 10 years onwards.

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2017
This article has no abstract
Epistemonikos ID: c89d039c88b711e6b7554b84aaafc9b734fdeb30
First added on: Jul 27, 2021